Cover Image
市場調查報告書

心絞痛 : 開發平台分析

Angina (Angina Pectoris) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219722
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
心絞痛 : 開發平台分析 Angina (Angina Pectoris) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 74 Pages
簡介

所謂心絞痛,是指心肌缺血(送給心肌的氧量不充足的狀態)使胸部產生疼痛的狀態。通常是在運動身體(辛勤勞動)時產生,休息便恢復。通常扁桃腺為冠狀動脈疾病的徵兆。可是最重症的情況,是僅些許行動和休息時的也發作。風險要素包含抽煙和久坐工作為中心的生活習慣,高血脂症,高膽固醇症等。主要的症狀有焦慮症,及心律的上升或不穩定化,臉色蒼白,冷汗,悲觀心情等。這樣的症狀與心臟病發作很相似。

本報告提供全球各國的心絞痛治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗各階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

心絞痛概要

治療藥的開發

  • 心絞痛開發中產品:概要
  • 心絞痛開發中產品:比較分析

各企業開發中的心絞痛治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

心絞痛治療藥:開發中的產品一覽(各企業)

心絞痛治療藥的開發企業

  • Baxalta Incorporated
  • Bayer AG
  • Cardiolynx AG
  • Gilead Sciences, Inc.
  • Juventas Therapeutics, Inc.
  • Kuhnil Pharmaceutical Co., Ltd.
  • Lacer, S.A.
  • Lee's Pharmaceutical Holdings Limited
  • LegoChem Biosciences, Inc
  • Milestone Pharmaceuticals, Inc.
  • Taxus Cardium Pharmaceuticals Group Inc.
  • ViroMed Co., Ltd.

心絞痛:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • aladorian sodium
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • alferminogene tadenovec
  • BAY-606583
  • CLC-1201
  • CLC-1280
  • eleclazine
  • JVS-100
  • KI-1007
  • LA-419
  • LA-8045
  • MSP-2017
  • 心絞痛的可溶性鳥苷酸環化酶活性化小分子
  • 冠狀動脈粥樣硬化、中風的血液因子 XIa 阻礙小分子
  • 心室心律不整的Ryanodine受體2拮抗小分子藥
  • 循環系統疾病的幹細胞療法
  • VM-202
  • ZK-001

心絞痛治療藥:開發中產品的最新趨勢

心絞痛治療藥:開發暫停的產品

心絞痛治療藥:開發中止的產品

心絞痛相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8578IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina - Pipeline Review, H2 2016, provides an overview of the Angina (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Angina (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 3 and 2 respectively for Angina.

Angina (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Angina (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Angina (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Angina (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Angina (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Angina (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Angina (Angina Pectoris) Overview
  • Therapeutics Development
    • Pipeline Products for Angina (Angina Pectoris) - Overview
  • Angina (Angina Pectoris) - Therapeutics under Development by Companies
  • Angina (Angina Pectoris) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Angina (Angina Pectoris) - Products under Development by Companies
  • Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Bayer AG
    • Juventas Therapeutics, Inc.
    • Kuhnil Pharmaceutical Co., Ltd.
    • Lee's Pharmaceutical Holdings Limited
    • LegoChem Biosciences, Inc
    • Milestone Pharmaceuticals, Inc.
    • Sanofi
    • Shire Plc
    • Taxus Cardium Pharmaceuticals Group Inc.
    • ViroMed Co., Ltd.
  • Angina (Angina Pectoris) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alferminogene tadenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-606583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erenumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etripamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KI-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-407899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Angina (Angina Pectoris) - Dormant Projects
  • Angina (Angina Pectoris) - Discontinued Products
  • Angina (Angina Pectoris) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
      • May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
      • Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
      • Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
      • May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
      • Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
      • Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients
      • Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
      • Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Angina (Angina Pectoris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Angina (Angina Pectoris) - Pipeline by Amgen Inc., H2 2016
  • Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2016
  • Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2016
  • Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016
  • Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2016
  • Angina (Angina Pectoris) - Pipeline by Sanofi, H2 2016
  • Angina (Angina Pectoris) - Pipeline by Shire Plc, H2 2016
  • Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016
  • Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Angina (Angina Pectoris) - Dormant Projects, H2 2016
  • Angina (Angina Pectoris) - Dormant Projects (Contd..1), H2 2016
  • Angina (Angina Pectoris) - Dormant Projects (Contd..2), H2 2016
  • Angina (Angina Pectoris) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Angina (Angina Pectoris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top